Flu Vaccine Maker Raises $23 Million
Vivaldi Biosciences Inc., a New York-based developer of influenza vaccines, has called down $18.85 million of a $23 million Series A round. Seed backers Bay City Capital and NGN Capital co-led the round, and were joined by New York City Investment Fund and Alexandria Real Estate Equities. The remaining capital can be called once certain milestones are met.
9 January 2009•4 mins read
